Amazon Debuts “Amazon Now” for 30-Minute Ultrafast Grocery Delivery 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Apple Appoints Amar Subramanya as New Vice President of AI Amid Push to Accelerate Innovation 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Samsung Launches Galaxy Z TriFold to Elevate Its Position in the Foldable Smartphone Market 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Merck KGaA (ETR: MRCG) strengthened its full-year 2025 outlook after posting higher third-quarter earnings, supported by strong momentum in its Healthcare and Life Science divisions despite ongoing softness in the Electronics segment. The German science and technology company now expects net sales between €20.8 billion and €21.4 billion and EBITDA pre of €6 billion to €6.2 billion, reflecting organic growth of 3% and 5–7%, respectively.
The updated forecast also factors in portfolio changes, including the July 2025 acquisition of SpringWorks Therapeutics and the divestment of the Surface Solutions business. Merck projects earnings per share pre of €8.20 to €8.60, based on a 22% tax rate, and anticipates operating cash flow between €3.6 billion and €4 billion.
Merck said organic sales growth will be led primarily by its Life Science and Healthcare sectors, with Electronics expected to decline. Within Healthcare, the company foresees continued strength from its Cardiovascular, Metabolism & Endocrinology franchise. Meanwhile, multiple sclerosis treatment Mavenclad is set to remain a growth driver, although its contribution may soften after a recent U.S. court ruling that enables competing products.
In the third quarter, Merck’s net sales rose 1% to €5.32 billion, while EBIT increased 11.3% to €1.22 billion, lifting the margin to 23%. EBITDA pre climbed 3.1% to €1.67 billion, and profit after tax advanced 10.6% to €898 million. These gains were supported by divestment-related income, including a €113 million disposal gain from the Surface Solutions sale and proceeds from a $175 million FDA priority review voucher transaction.
Healthcare sales reached €2.2 billion, driven by strong performances from Mavenclad and oncology therapy Erbitux. Life Science revenue increased to €2.24 billion, supported by robust demand in Process Solutions. Electronics revenue declined 5.2% to €875 million following the divestment.
Merck ended the quarter with €1.52 billion in operating cash flow and net financial debt of €9.29 billion, reflecting new bond issuances and the SpringWorks acquisition. The company expects 2025 to remain volatile due to macroeconomic and currency factors, with the euro–U.S. dollar exchange rate likely staying between 1.11 and 1.15.
